Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W G Tracewell

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Pharmacokinetics|May 21, 1998
Pharmacokinetics and pharmacodynamics of hydroxyureaP R Gwilt, W G Tracewell
Clinical Pharmacokinetics|June 1, 1991
The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humansP R Gwilt, R R Nahhas, W G Tracewell
Journal of Pharmaceutical Sciences|July 1, 1994
Nonlinear disposition of hydroxyureaW G Tracewell, W P Vaughan, P R Gwilt
Antisense Research and Development|January 1, 1994
Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusionP L Iversen, J Mata, W G Tracewell, et al.
Pharmacotherapy|February 20, 1998
Population pharmacokinetics of glyburide in patients with well-controlled diabetesW G Tracewell, D J Stalker, P A Maloley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Population pharmacokinetics of hydroxyurea in cancer patientsW G Tracewell, D L Trump, W P Vaughan, et al.
Biopharmaceutics & Drug Disposition|October 20, 2000
Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and womenS K Teo, M R Scheffler, K A Kook, et al.
Journal of Clinical Pharmacology|June 14, 2001
Thalidomide dose proportionality assessment following single doses to healthy subjectsS K Teo, M R Scheffler, K A Kook, et al.
Journal of Hematotherapy & Stem Cell Research|May 17, 2000
Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swineJ E Mata, J D Jackson, S S Joshi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Pharmacokinetics|May 21, 1998
Pharmacokinetics and pharmacodynamics of hydroxyureaP R Gwilt, W G Tracewell
Clinical Pharmacokinetics|June 1, 1991
The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humansP R Gwilt, R R Nahhas, W G Tracewell
Journal of Pharmaceutical Sciences|July 1, 1994
Nonlinear disposition of hydroxyureaW G Tracewell, W P Vaughan, P R Gwilt
Antisense Research and Development|January 1, 1994
Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusionP L Iversen, J Mata, W G Tracewell, et al.
Pharmacotherapy|February 20, 1998
Population pharmacokinetics of glyburide in patients with well-controlled diabetesW G Tracewell, D J Stalker, P A Maloley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Population pharmacokinetics of hydroxyurea in cancer patientsW G Tracewell, D L Trump, W P Vaughan, et al.
Biopharmaceutics & Drug Disposition|October 20, 2000
Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and womenS K Teo, M R Scheffler, K A Kook, et al.
Journal of Clinical Pharmacology|June 14, 2001
Thalidomide dose proportionality assessment following single doses to healthy subjectsS K Teo, M R Scheffler, K A Kook, et al.
Journal of Hematotherapy & Stem Cell Research|May 17, 2000
Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swineJ E Mata, J D Jackson, S S Joshi, et al.
Pageof 1